Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer

NCT06225427 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT06225427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06225427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
July 25, 2024
Completion date
May 31, 2027
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lung non-small cell carcinoma, stage iv lung cancer ajcc v8